Live Breaking News & Updates on Canadian Cardiovascular Society

Stay updated with breaking news from Canadian cardiovascular society. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Roche granted FDA Breakthrough Device Designation

Roche announces that the Tina-quant lipoprotein Lp(a) RxDx assay receives Breakthrough Device Designation from the FDA ....

Beijing , China , Canada , Canadian , Matt-sause , European-atherosclerosis-society , Canadian-cardiovascular-society , Amgen , Heart-society , European-society-of-cardiology , National-lipid-association , Drug-administration

Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) – a key marker for hereditary cardiovascular risk

Approximately one in five people worldwide have elevated Lp levels, putting them at increased risk of cardiovascular diseases including myocardial infarction and stroke.1The Roche Diagnostics. ....

Copenhagen , Køavn , Denmark , Kamstrup , Sjæand , Langsted , Syddanmark , Switzerland , Japan , Beijing , China , United-states

F. Hoffmann-La Roche Ltd: Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) - a key marker for hereditary cardiovascular risk

Approximately one in five people worldwide have elevated Lp(a) levels, putting them at increased risk of cardiovascular diseases including myocardial infarction and stroke.1The Roche Diagnostics Tina-quant® ....

Kamstrup , Sjæand , Denmark , Langsted , Syddanmark , Japan , Copenhagen , Køavn , Canada , Beijing , China , United-states

FDA Grants Tina-qant Lp(a) Assay Breakthrough Device Designation

A lipoprotein (a) (Lp[a]) assay has been granted breakthrough device designation to expand identification of patients with elevated Lp(a) and genetic predispositions to cardiovascular disease.
....

United-states , Canada , Canadian , American , National-heart , European-atherosclerosis-society , Blood-institute , American-heart-association , Canadian-cardiovascular-society , Device-designation , Show-lepodisiran-was-well-tolerated

Responders to PCI for Angina Relief Identified by Chest Pain Type

Typical angina predicted PCI's efficacy in ORBITA-2 ....

Canada , Boston , Massachusetts , United-states , Paris , France-general , France , Lebanon , London , City-of , United-kingdom , Canadian